Pembrolizumab demonstrated superior disease-free survival (DFS) compared with placebo as adjuvant therapy in patients with renal cell carcinoma in Phase 3 KEYNOTE-564 trial.

RCT (n=950) found that pemsrolizumab monotherapy was linked to a statistically significant improvement in DFS vs placebo. The trial will continue to evaluate overall survival (OS), a key secondary endpoint. Date to be presented at upcoming meeting.

Biospace Inc.